- Research works
- 20 ▲ 139% vs 2013–17
- Citations
- 269 13.1 per fractional work
- Top-10% rate
- 8.3% record average 16.5%
- Open access
- 42% world 28%
Not ranked overall: Apexigen (United States) is under the volume floor below which an excellence rate is noise. Not ranked is not the same as ranked last.
Field profile
Location quotient across every field it publishes in: outside the ring is more than an institution of this size would be expected to publish, inside it is less.
Rings at 0.5×, 1× and 2×. Widest outward: Immunology and Microbiology, 13.3×. Every wedge is a field page.
Which keywords describe research at Apexigen (United States)?
By fractional works in all years, weighted toward what it does more of than the world: Cancer Immunotherapy, Immunity, Antigen Presentation, Dendritic Cells, Glycosylation, Immunotherapy, Tumor Microenvironment and Monoclonal Antibodies.
- Chimeric Antigen Receptor
- Macrophage
- Lymphoma
- Cancer
- Inflammation
- PD-1 and PD-L1
- Monoclonal Antibodies
- Immunotherapy
- Dendritic Cells
- Immunity
- Cancer Immunotherapy
- Antigen Presentation
- Glycosylation
- Tumor Microenvironment
- Immune Checkpoint Blockade
- Fc Receptors
- Therapeutic Antibodies
- Tumor Regression
- Activation
- CAR T Cells
Size is fractional works in all years in the topics tagged with each word; colour is the word's share of this institution's work against its share of the world's. The 20 words are chosen for being large and distinctive. Each links to the topic it comes from most.
All 20 words, with their numbers
- Cancer Immunotherapy6▲ 215×3 topics
- Immunity6▲ 81×2 topics
- Antigen Presentation4▲ 213×1 topic
- Dendritic Cells4▲ 185×1 topic
- Glycosylation2▲ 44×2 topics
- Immunotherapy2▲ 15×8 topics
- Tumor Microenvironment2▲ 26×2 topics
- Monoclonal Antibodies2▲ 62×2 topics
- Immune Checkpoint Blockade2▲ 147×1 topic
- PD-1 and PD-L12▲ 147×1 topic
- Fc Receptors2▲ 81×1 topic
- Inflammation2▲ 3.4×4 topics
- Therapeutic Antibodies2▲ 63×1 topic
- Cancer2▲ 5.4×4 topics
- Tumor Regression2▲ 85×2 topics
- Lymphoma1▲ 45×2 topics
- Activation1▲ 174×1 topic
- Macrophage1▲ 108×1 topic
- CAR T Cells1▲ 129×1 topic
- Chimeric Antigen Receptor1▲ 129×1 topic
Which research topics does Apexigen (United States) publish most on?
By volume in 2022–2025: Cancer Immunotherapy and Biomarkers, CAR-T cell therapy research, Immunotherapy and Immune Responses and Computational Drug Discovery Methods.
Area is fractional works; colour is the subfield each topic belongs to.
- 1 Cancer Immunotherapy and Biomarkers Oncology 1 works
- 2 CAR-T cell therapy research Oncology 1 works
- 3 Immunotherapy and Immune Responses Immunology 1 works
- 4 Computational Drug Discovery Methods Computational Theory and Mathematics 0 works
- 5 Arts, Culture, and Music Studies Cultural Studies 0 works
- 6 Libraries and Information Services Museology 0 works
- 7 Mathematical Biology Tumor Growth Modeling and Simulation 0 works
- 8 Microtubule and mitosis dynamics Cell Biology 0 works
- 9 Advanced Biosensing Techniques and Applications Molecular Biology 0 works
- 10 Museums and Cultural Heritage Museology 0 works
How open and international is its research?
Against the world’s own shares — the tick on each track. Both are shares of its output, so they sit on one scale and can be read against each other as well as against the world.
World: 28% of research is openly available.
World: 19% is written across borders.
How has Apexigen (United States)'s research output changed?
Output in 2018–2022 was 139% higher than in 2013–2017.
The same series as a ribbon — one cell per year, darker for more. The line above answers how much; this answers when.
Other research institutions in San Carlos
- Natera (United States)
- Protein Metrics (United States)
- TiVo (United States)
- Go2 for Lung Cancer
- Natus (United States)
- Cellerant Therapeutics (United States)
- Rosa (United States)
- Allakos (United States)
Research measures only: rankings here say nothing about teaching, admissions or student experience. Comparable institutions and collaboration partners are in the interactive view on the map.